BYON Co., Ltd. Overview
BYON Co., Ltd. is a 43-year-old Korean corporate shell with a long history of business reinvention. It began as Seoul Electron, an electronics company, and later operated as Polyvision, which made PVC advertising banners, tarpaulins and flooring. From 2016 it repositioned under the BYON name as a "bio-medical" company. In practice, most of its revenue came from trading high-pressure-processed red ginseng raw materials, supported by a minority stake in stem-cell developer MiraeCell Bio. From late 2023, a change of control to CTM Co., Ltd. pushed the business into unrelated industrial assets: hydraulic machinery (CM Tech), a minority stake in Gwangjin Sanjeon, fuel sales and ship components. Repeated failed control transfers, disclosure violations, and criminal complaints against management followed. The company recorded net losses every year from FY2015 to FY2025, received a disclaimer audit opinion for FY2025, and was delisted from KOSDAQ on 1 July 2026.
Company's own description (latest available investor material)
The most recent investor-relations presentation found is the May 2021 IR deck [S18]. It described BYON as a KOSDAQ-listed small or medium enterprise whose main businesses were cosmetics manufacturing and sales, plus distribution of health functional food raw materials. The deck organised operations into three divisions: Bio-medical, at roughly 82% of FY2020 separate revenue; Cosmetics, at roughly 9%; and Auto parts, at roughly 1%. The deck made five main points:
Bio-medical: The core activity was processing ginseng into red ginseng raw materials using high-pressure technology. Supply came from a farm partner in Geumsan under a December 2015 alliance with Baeknyeon F&G. The output was sold as an input for cosmetics, pharmaceuticals and health supplements. Customers included large domestic companies and pharmaceutical firms; the deck names Amorepacific and Ilyang Pharmaceutical [S18].
Stem cells: BYON held 23.53% of affiliate MiraeCell Bio (미래셀바이오), which was developing stem-cell therapies and preparing for a KOSDAQ technology-special listing [S18].
Medical devices: BYON planned to build a GMP facility for contract manufacturing of stem-cell-applied wound dressings and in-vitro diagnostic devices. For this it acquired roughly 940 m² in the Gwangmyeong medical cluster [S18].
Financial profile: Management stressed a "no-borrowing" stance: a debt ratio of 19.13% and current ratio of 347.90% at FY2020 (consolidated) [S18].
Third-party profiles based on later filings describe a broader and more fragmented business. Stockopedia reported that the company ran eight reporting segments: bio-medical, cosmetics, health supplements, fuel sales, ship components, hydraulic motors, automotive parts, and others [S25]. Simply Wall St and Morningstar describe stem-cell cell-therapy development and cardiomyocyte commercialisation, supply of health functional food ingredients, and cosmetics, cosmetic containers and auxiliary materials [S13a][S26].
Independent characterisation
Based on the filing trail, BYON is best understood as a listed holding vehicle whose operating mix followed whoever controlled it, not as a focused operating company:
1983–2015 (Seoul Electron / Polyvision era): industrial products. These included advertising banners ("banner flex"), tarpaulins and PVC flooring, made at a plant in Ochang, Chungcheongbuk-do [S23][S24].
- 2016–2023 (BYON "bio" era, under the Kim Byung-joon management): a trading-led red-ginseng raw-material business. Smaller contributions came from cosmetics (including the STEMELIN brand launched in 2022), auto-parts trading, and furniture or beauty-device trading. The bio narrative depended on equity stakes in MiraeCell Bio and other affiliates rather than on in-house R&D. Disclosed R&D spend never exceeded ₩1.3 billion a year.
2024–2026 (CTM era, under CEO Ryu Jin-hyung): the company bought industrial assets connected to its new controlling shareholder. It took 28% of Gwangjin Sanjeon in March 2024 [S10] and 100% of CM Tech, a heavy-equipment parts and hydraulic machinery maker, in May 2024 [S17]. By 2025, Pharmatimes reported that most revenue came from fuel and ship-parts sales, while bio-medical revenue had fallen from ₩9.6 billion in 2021 to ₩0.2 billion in 2024 [S6].
Business model and revenue model
| Dimension | Assessment |
|---|---|
| Product vs. service vs. subscription vs. licensing | Almost entirely product sales and merchandise trading. The 2018–2021 segment tables classify bio-medical, cosmetics and auto-parts revenue as merchandise (상품) sales, not manufactured goods [S18]. No subscription or licensing revenue is disclosed. |
| Value-chain position | Mid-stream processor and trader of red ginseng raw materials (2016–2023), then a downstream holder of industrial operating subsidiaries (2024–2026) |
| Customer types | B2B: large consumer-goods and cosmetics firms, pharmaceutical companies, food companies, shipyards and industrial buyers. Limited B2C through the STEMELIN cosmetics brand via home shopping [S27]. |
| End-markets | Korean health functional foods, cosmetics, automotive parts, hydraulic machinery and heavy equipment parts, marine and ship components, fuel distribution |
| Revenue concentration | High. In FY2020, one product category (red ginseng raw materials) made up 81.76% of separate revenue [S18]. |
Strategy
Stated strategy (2021 IR, the last formal strategy statement found)
The May 2021 IR deck set out four strategic priorities [S18]:
-
Expand health functional food raw-material sales, including a first-tier vendor contract with Ilyang Pharmaceutical.
-
Pursue stem-cell value through affiliate MiraeCell Bio's planned KOSDAQ technology listing.
-
Enter wound-dressing and IVD contract manufacturing via a GMP facility in the Gwangmyeong medical cluster.
-
Maintain a no-borrowing financial stance.
None of these produced disclosed results. Bio-medical revenue collapsed by 2024 [S6]. No MiraeCell Bio listing was found in the sources reviewed. No GMP facility revenue was disclosed. Borrowings rose to about ₩24.9 billion by 2026 [S20].
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Timing | Outcome |
|---|---|---|
| Industrial diversification under CTM (CM Tech hydraulics, Gwangjin Sanjeon, fuel and ship-component trading) | 2024–2025 | Raised consolidated revenue in FY2024 but not profitability. Subject of embezzlement and breach-of-trust complaints [S16][S17]. |
| Control sale to N Four Space / Oh Young-hoon | Jul–Dec 2024 | Failed for non-payment. The late disclosure triggered unfaithful-disclosure penalties [S14][S15]. |
| ₩1.0bn follow-on placement at ₩577 per share | Filed Dec 2024 | Small liquidity injection [S19] |
| Injunction against delisting | Aug 2025 – Jun 2026 | Delayed liquidation trading by about 10 months. Trading eventually resumed and the shares were delisted on 1 Jul 2026 [S1][S7]. |
| ESG or sustainability programmes | — | None disclosed |
| Cost programmes with targets | — | None disclosed |
| Medium-term financial targets / guidance | — | None disclosed |
Products & Services
The table covers every product or offering identifiable in public sources. BYON never published a priced catalogue. Specifications, launch years and pricing are given only where disclosed.
Bio-medical / health functional food raw materials
| Product | Description | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| Red ginseng concentrate (홍삼농축액) | Red ginseng processed from Geumsan ginseng with high-pressure technology. The company says the process reduces split roots and internal cavities and lowers defect rates. | Large consumer-goods, cosmetics and pharmaceutical companies (Amorepacific and Ilyang Pharmaceutical named) | Since Dec 2015 | — |
| Red ginseng powder (홍삼분말) | Same process; powder format | Same | Since Dec 2015 | — |
| Red ginseng slices (홍삼절편) | Same process; sliced format | Same | Since Dec 2015 | — |
| Secondary processed health products | Health functional foods made from the above raw materials and supplied to customers | B2B | Ongoing as of 2021 | — |
Source: [S18]. The 2021 deck also refers to a first-tier vendor contract with Ilyang Pharmaceutical [S18].
Stem-cell and medical-device initiatives (largely through affiliate MiraeCell Bio)
| Item | Description | Status as last disclosed | Source |
|---|---|---|---|
| MR-MC-01 | Embryonic-stem-cell-derived therapy for interstitial cystitis. Designated an orphan drug (No. 30) by MFDS. Described as a world-first Phase 1 approval in May 2020. | Phase 1 / investigator studies ongoing (2021) | [S18] |
| MMSC | Allogeneic embryonic-stem-cell-derived mesenchymal stem-cell therapy platform | Clinical development funded by a ₩10 billion Pre-IPO round (Oct 2020) | [S18] |
| Atopic dermatitis therapy | Pluripotent-stem-cell-based; clinical trial at Asan Medical Center | Ongoing (2020–2021) | [S18] |
| Human adipose stem-cell conditioned media | Cosmetic ingredient that meets MFDS standards. First listed in the International Cosmetic Ingredient Dictionary in 2010. | Commercial ingredient | [S18][S27] |
| Stem-cell-applied wound dressings | Planned contract-manufacturing product for a GMP facility in the Gwangmyeong medical cluster | Planned (2021); no later commercialisation found | [S18] |
| In-vitro diagnostic device contract manufacturing | Planned CMO service | Planned (2021); no later commercialisation found | [S18] |
| Cardiomyocyte commercialisation | Cited in third-party profiles as a stem-cell-based business objective | No product, approval or revenue disclosed | [S13a][S26] |
Affiliate IP cited by the company includes a US patent for a "dementia pig" model (Sept 2019), a Korean patent on mammoth-cell culture (Dec 2019), and stem-cell in-vivo tracking technology (Feb 2021) [S18]. These belong to MiraeCell Bio, not to BYON.
Cosmetics
| Product | Description | Channel | Launch |
|---|---|---|---|
| STEMELIN (스템엘린) brand | Anti-ageing cosmeceutical line built around stem-cell conditioned media, with collagen extract, elastin and hyaluronic acid | Home shopping and online | Aug 2022 (home-shopping launch) [S27] |
| STEMELIN Hyper Active Cell Ampoule | Flagship ampoule of the STEMELIN line | Home shopping | Aug 2022 [S27] |
| Basic and colour cosmetics (merchandise) | Traded cosmetics. Revenue ₩4.89 billion in FY2018, falling to ₩1.35 billion in FY2020. | B2B / B2C | Pre-2018 [S18] |
| Cosmetic containers and auxiliary materials | Cited in third-party profiles | — | — |
Industrial and other
| Product line | Description | Period | Source |
|---|---|---|---|
| Banner flex | Plastic (PVC) advertising banner material | Polyvision era; still listed as the main product on some aggregators | [S23] |
| Tarpaulins, PVC flooring | Industrial products; Ochang plant; flooring via subsidiary Polyfloor | Polyvision era | [S24][S18] |
| Auto parts (merchandise) | Injection-moulded parts and seat fabrics | Until FY2019; minor in Q1 2021 | [S18] |
| Hydraulic motors / hydraulic machinery and parts | Through CM Tech | From 2024 | [S17][S25] |
| Ship components | Segment cited in later filings | 2024–2025 | [S6][S25] |
| Fuel sales | Segment cited in later filings; reported as a main 2025 revenue source | 2024–2025 | [S6][S25] |
| Beauty devices and furniture | "Other" merchandise | 2018–2021 | [S18] |
Financial Narrative
Data basis and caveats
Primary consolidated series: S&P Global Market Intelligence data as published by Simply Wall St, FY2015 to LTM Q1 2026 [S19]. Covers revenue, net income, G&A and R&D.
Company-reported series: the May 2021 IR deck, covering FY2019, FY2020 and Q1 2021 on both consolidated and separate bases [S18].
FY2025 separate figures: from the company's preliminary disclosure as reported by Topstarnews [S5] and iNews24 [S2].
Basis difference: FY2025 consolidated revenue was about ₩20.6 billion (S&P) [S19], but FY2025 separate revenue was ₩3.25 billion [S5]. Consolidated figures include CM Tech and the other 2024 acquisitions; separate figures are the listed parent alone. KRX listing tests (such as the ₩300 million quarterly revenue test) applied to the separate figure.
FY2025 is not audited in substance: because of the disclaimer of opinion [S2].
- EPS, dividends per share, EBITDA, gross profit and operating income were not available for FY2021–FY2024 in the sources reviewed. Blank cells below mean not publicly disclosed / not available in the sources reviewed.
Income statement: consolidated
Sources: revenue, net income, G&A and R&D from [S19]. Margins and growth are computed. The FY2021 growth rate is against FY2020 revenue of ₩22,232 million [S18][S19]. Stockopedia confirms no dividend was paid [S25].
Revenue CAGR FY2021–FY2025 (consolidated): about 16.3%, matching Simply Wall St's reported 5-year revenue growth rate of 16.30% [S19]. The figure overstates operating health: the FY2024 jump came from acquired businesses, not organic growth.
Longer consolidated context
Sources: [S19]. Operating income for FY2019 and FY2020 is from the company IR deck [S18]. The IR deck shows consolidated net losses of ₩21,632 million (FY2019) and ₩6,404 million (FY2020) [S18], slightly different from the S&P figures (₩21,502 million and ₩6,365 million). The gap likely reflects attributable vs. total net income; both are shown.
Loss record: S&P data shows a consolidated net loss in every fiscal year from FY2015 through FY2025, eleven consecutive years [S19]. Asia Economy described six consecutive years of losses as of November 2023 [S8].
Separate (parent-only) income statement: notes and sources
Sources: FY2019–FY2020 from [S18]. FY2025 revenue (₩3,247,476,792) and operating loss (₩1,993,525,351) from [S5]. The FY2024 separate revenue of about ₩5,578 million is derived from the disclosed 41.79% FY2025 decline [S5]; it is not a reported figure.
Balance sheet: consolidated
Sources: FY2019, FY2020 and Q1 2021 from the company IR deck [S18]. Q1FY2026 from Simply Wall St (S&P) [S20], whose page is dated 30 June 2026 and uses earnings to 31 March 2026. Net debt and working capital are computed. FY2021–FY2025 year-end balance sheets were not available in the sources reviewed.
FY2025 separate liquidity points (iNews24) [S2]:
-
Current assets of about ₩5.1 billion, roughly half the prior year.
-
Current liabilities of about ₩14.4 billion.
-
Cash and equivalents of about ₩150 million, down about 80%.
-
A ₩1.8 billion short-term financial instrument position fully liquidated.
THE VC reports that the separate current ratio fell from 359.8% (FY2023) to 19.3% (FY2024) [S23].
Cash flow: notes and sources
Source: [S18]. Capex, dividends paid and buybacks were not separately disclosed. No dividends or buybacks are recorded. Simply Wall St flagged trailing free cash flow of about −₩3.2 billion in late 2024 and less than one year of cash runway [S20].
Ratios
Sources: FY2019–FY2020 ratios from [S18], with debt/equity computed from 6.5. Q1FY2026 ROE, net margin and debt/equity from [S19][S20]; current ratio and liabilities/equity computed. ROA, ROIC, interest coverage (n/a on negative EBIT [S20]), asset turnover and cash conversion cycle cannot be computed reliably from the available data.
Commentary on trends, inflections and drivers
FY2019 → FY2020: the only real inflection. COVID-era demand for immunity products lifted red-ginseng raw-material sales; bio-medical segment revenue rose about 94% to ₩12.8 billion [S18]. BYON also exited cosmetics manufacturing, which had been a margin drag, and recovered a long-overdue receivable from its Beijing associate. Together these moved the consolidated operating loss from −₩10.3 billion to −₩0.55 billion and produced a separate operating profit of ₩2.68 billion [S18]. Borrowings fell from ₩21.3 billion to ₩4.7 billion after collateralised assets were sold and convertible bonds were converted or repurchased [S18]. This is the period management presented as a stable, "no-borrowing" balance sheet.
FY2021 → FY2023: erosion. Consolidated revenue roughly halved in FY2021 to ₩11.2 billion and fell to ₩8.9 billion by FY2023 [S19]. Net losses continued at ₩7–13 billion a year. G&A expense rose from ₩6.0 billion to ₩7.3 billion while revenue shrank, taking G&A to 82% of revenue in FY2023. Funding came mainly from equity and convertible-bond issuance, including the ₩8.0 billion 39th CB in June 2021 and roughly ₩1.0 billion follow-on placements. Simply Wall St recorded 8.5–19% annual shareholder dilution in this period [S19][S20].
FY2024: acquisition-driven revenue spike, no profit improvement. Revenue tripled to ₩27.0 billion after the purchase of CM Tech and the start of fuel and ship-component trading, but the net loss widened to ₩8.9 billion and G&A rose to ₩10.1 billion [S19]. The acquisitions were funded with convertible bonds (₩10.5 billion 41st series; ₩10.0 billion 42nd series) whose validity was challenged in court in September 2024 [S13]. The separate current ratio fell from 359.8% to 19.3% [S23]. The parent's liquidity effectively disappeared as cash moved into related-party and acquisition assets.
FY2025 → Q1 2026: terminal phase. Consolidated revenue fell 24% to ₩20.6 billion, with a net loss of ₩6.6 billion [S19]. Parent-only revenue fell 41.79% to ₩3.25 billion [S5]. Cash at the parent was about ₩150 million [S2]. On a consolidated basis, total borrowings of about ₩24.9 billion against equity of ₩16.3 billion gave debt/equity of 152.5%, up from about 15% five years earlier [S20]. LTM revenue to March 2026 fell further to ₩11.9 billion [S19]. The auditor's going-concern disclaimer [S2] is consistent with these numbers.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents (company description) | Revenue type |
|---|---|---|
Bio-medical (바이오의료) | Health-food raw materials, mainly red ginseng concentrate, powder and slices made with high-pressure processing. Also includes stem-cell-related affiliate holdings (MiraeCell Bio) and the planned GMP medical-device project. | Merchandise |
Cosmetics (화장품) | Basic and colour cosmetics. Cosmetics manufacturing was being wound down by 2020 to improve margins. | Merchandise |
Auto parts (자동차부품) | Injection-moulded parts and seat fabrics | Merchandise |
Other (기타) | Beauty devices, furniture and similar | Merchandise |
Revenue by Segment
| Segment | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Bio-medical revenue (KRW Mn) | 8,080 | 6,586 | 12,809 |
Cosmetics revenue (KRW Mn) | 4,894 | 2,275 | 1,345 |
Auto parts revenue (KRW Mn) | 2,784 | 1,217 | 0 |
Other revenue (KRW Mn) | 751 | 316 | 1,513 |
Total separate segment revenue (KRW Mn) | 16,509 | 10,394 | 15,667 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Bio-medical share of revenue (%) | 48.94 | 63.36 | 81.76 |
Cosmetics share of revenue (%) | 29.64 | 21.89 | 8.58 |
Auto parts share of revenue (%) | 16.86 | 11.71 | 0 |
Other share of revenue (%) | 4.55 | 3.04 | 9.66 |
Bio-medical YoY growth (%) | — | -18.5 | 94.5 |
Cosmetics YoY growth (%) | — | -53.5 | -40.9 |
Auto parts YoY growth (%) | — | -56.3 | -100.0 |
Revenue by Segment (FY2021–FY2024)
| Segment | FY2021 | FY2024 |
|---|---|---|
Bio-medical revenue (KRW Mn) | 9,600 | 200 |
Group Entities
| Entity | Relationship | Stake (%) |
|---|---|---|
Polyfloor Co., Ltd. (폴리플로어) | Subsidiary (legacy flooring business) | 81.37 |
MiraeCell Bio Co., Ltd. (미래셀바이오) | Associate; stem-cell therapies | 23.53 |
Beijing company (북경원일차식유한공사), China | Associate | 47.00 |
Gwangmyeong Hana BYON (광명하나바이온) | Associate | 14.00 |
BYON Meditech Co., Ltd. (바이온메디테크) | Subsidiary | 100.00 |
K-Star Entertainment (케이스타엔터테인먼트) | Associate | 42.86 |
Anti-Aging Co., Ltd., Japan (안티에이징) | Associate | 50.00 |
BYON Global Co., Ltd. (바이온글로벌) | Subsidiary | 100.00 |
Group Entities — Gwangjin Sanjeon
| Entity | Business | Stake / cost | Date |
|---|---|---|---|
Gwangjin Sanjeon (광진산전) | Industrial operating company; specific product line not disclosed in the sources reviewed | 28% for ₩6.02 billion | 7 Mar 2024 |
CM Tech (씨엠텍) | Heavy-equipment parts and hydraulic machinery and parts manufacturing | 100% for ₩11.0 billion | 2024, after the 41st CB in May |
GN Equity (지엔에쿼티) | Real-estate leasing and trading, newly established | ₩1.5 billion capital contribution | 4 Jul 2024 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 11,239 | 12,877 | 8,889 | 26,956 | 20,596 |
Revenue YoY growth (%) | -49.4 | 14.6 | -31.0 | 203.3 | -23.6 |
Net income (KRW Mn) | -13,361 | -9,793 | -6,978 | -8,851 | -6,606 |
G&A expense (KRW Mn) | 5,999 | 6,711 | 7,297 | 10,095 | 6,208 |
R&D expense (KRW Mn) | 30 | 238 | 259 | 644 | 21 |
Net margin (%) | -118.9 | -76.1 | -78.5 | -32.8 | -32.1 |
G&A as % of revenue (%) | 53.4 | 52.1 | 82.1 | 37.4 | 30.1 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 23,199 | 18,146 | 35,047 | 19,624 | 22,232 |
Net income (KRW Mn) | -2,057 | -5,369 | -10,492 | -21,502 | -6,365 |
Operating income (KRW Mn) | — | — | — | -10,293 | -553 |
Income Statement and Margin Analysis (%) (FY2019–FY2025)
| Metric | FY2019 | FY2020 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenue (KRW Mn) | 10,408 | 15,667 | 5,578 | 3,247 |
Operating income (KRW Mn) | -4,704 | 2,680 | — | -1,994 |
Net income (KRW Mn) | -18,172 | -11,176 | — | — |
Operating margin (%) | -45.2 | 17.1 | — | -61.4 |
Balance Sheet
| Metric | FY2019 | FY2020 | Q1FY2021 | Q1FY2026 |
|---|---|---|---|---|
Total assets (KRW Mn) | 61,438 | 46,359 | 47,367 | 52,490 |
Current assets (KRW Mn) | 23,998 | 20,382 | 19,802 | 6,100 |
Cash and equivalents (KRW Mn) | 5,554 | 14,079 | 10,346 | 104 |
Total liabilities (KRW Mn) | 27,051 | 7,444 | 8,927 | 36,170 |
Current liabilities (KRW Mn) | 17,863 | 5,858 | 5,865 | 15,200 |
Non-current liabilities (KRW Mn) | 9,188 | 1,585 | 3,061 | 21,000 |
Total borrowings incl. CBs and leases (KRW Mn) | 21,287 | 4,720 | 6,356 | 24,900 |
Short-term borrowings (KRW Mn) | 1,081 | 1,042 | 1,000 | — |
Long-term borrowings (KRW Mn) | 4,959 | 0 | 1,380 | — |
Convertible bonds (KRW Mn) | 14,244 | 3,320 | 3,468 | — |
Net debt (KRW Mn) | 15,733 | -9,359 | -3,990 | 24,796 |
Total equity (KRW Mn) | 34,387 | 38,915 | 38,440 | 16,330 |
Intangible assets (KRW Mn) | 2,727 | 315 | 53 | — |
Investments in subsidiaries and associates (KRW Mn) | 14,055 | 16,296 | 16,393 | — |
Working capital (KRW Mn) | 6,135 | 14,524 | 13,937 | -9,100 |
Cash Flow
| Metric | FY2019 | FY2020 | Q1FY2021 |
|---|---|---|---|
Operating cash flow, consolidated (KRW Mn) | -2,556 | 3,110 | -2,727 |
Investing cash flow, consolidated (KRW Mn) | -2,521 | 10,937 | -3,152 |
Financing cash flow, consolidated (KRW Mn) | 4,956 | -5,650 | 2,146 |
Operating cash flow, separate (KRW Mn) | -1,116 | 4,579 | -2,447 |
Margin Analysis (%)
| Ratio | FY2019 | FY2020 | Q1FY2026 |
|---|---|---|---|
Current ratio, consolidated (%) | 134.35 | 347.90 | 40.1 |
Liabilities / equity, consolidated (%) | 78.67 | 19.13 | 221.5 |
Debt / equity (%) | 61.9 | 12.1 | 152.5 |
Return on equity (%) | — | — | -34.47 |
Net margin (%) | — | — | -50.78 |
Share Price History
| Date | Price (KRW) | Context |
|---|---|---|
10 Jul 2020 | 992 | Pre-COVID-rally reference |
4 Nov 2020 | 1,955 | 90-day high during the red-ginseng demand surge |
10 Mar 2021 | 1,270 | 90-day low |
Date not specified | 1,118 | Stockopedia reference; −14.25% over the preceding 365 days |
12 Nov 2023 | ~1393 | Implied: the CTM average price of ₩3,344 was described as 140% above the prior close |
Jul 2024 | 1,185 | Price at the July 2024 control-transfer contract |
27 Feb 2025 | 604 | −73.08% over the preceding 365 days |
25 Jun 2026 | 16 | Liquidation trading |
26 Jun 2026 | 8 | Liquidation trading |
29 Jun 2026 | 5 | Liquidation trading |
30 Jun 2026 | 2 | Final trade before delisting |
Valuation Snapshot
| Metric | Value |
|---|---|
1-year return to 27 Feb 2025 | −73.08% [S11a] |
H1 2026 return | −99.67%, the worst on KOSDAQ [S29] |
3-year and 5-year total return | Not computed precisely. From roughly ₩1,270–1,955 (2020–2021) to ₩2 (June 2026), the loss is effectively 99.9%. Interim share consolidation (see 9.4) may make unadjusted comparisons inexact. |
Valuation Snapshot by Multiple
| Multiple | Value | Note |
|---|---|---|
P/E | n/m (negative earnings) | Stockhub showed −2.16 TTM, on stale data [S28] |
EV/EBITDA | n/m | EBITDA negative or undisclosed |
EV/Sales | ~1.2x | Computed: about ₩24.8bn net debt plus ₩60.8m market cap at delisting, against LTM revenue of ₩11.9bn. Indicative only. |
P/B | ~0.00x at delisting | Market cap ₩60.8m vs. book equity ₩16.3bn [S19][S20] |
Peer multiples | Not compiled | — |
Capital Markets
| Item | Status |
|---|---|
Dividend history | No dividends paid [S25] |
Dividend policy | None disclosed |
Buyback authorisations | None disclosed |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Analyst consensus | None (0 analysts) [S19] |
Capital Instruments
| Instrument | Issue date | Amount (KRW) | Conversion price (KRW) | Status |
|---|---|---|---|---|
37th CB | Before 2021 | 1500000000 outstanding at Q1 2021 | — | — |
38th EB | Before 2021 | 3000000000 outstanding at Q1 2021 | — | — |
39th CB | 4 Jun 2021 | 8,000,000,000 | 1392 at issue; 892 at June 2024 conversion | ₩3.8bn converted June 2024 (4,260,086 shares); originally maturing 4 Jun 2024 |
40th CB | — | 1,500,000,000 | — | Convertible from March 2024 into 1,335,707 shares |
41st CB | 16 May 2024 | 10,500,000,000 | 898 | Validity challenged (Sept 2024 suit) |
42nd CB | 2024 | 10,000,000,000 | — | Validity challenged (Sept 2024 suit) |
Third-party allotment | 8 Apr 2021 | ~5000000000 | ~1215 implied (₩5.0bn / 4,115,226 shares) | Completed |
Third-party allotment (CTM) | Nov 2023 | 7,000,000,000 | 1,231 | Completed |
Follow-on placements | 2020–2024 | ~1000000000 each | 1260; 1430; 1146; 577 | Completed |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
None. BYON issued no financial guidance in the period reviewed. After delisting, it has no exchange-disclosure obligation, and no post-delisting corporate communication was found as of 16 October 2026.
Consensus expectations
None. There is no analyst coverage [S19].
Bull-case arguments (grounded, with low probability)
-
Residual asset value. Consolidated book equity was about ₩16.3bn at Q1 2026 [S20], including 100% of CM Tech (bought for ₩11.0bn) and 28% of Gwangjin Sanjeon (₩6.02bn) [S17][S10]. If these assets are realisable near cost, shareholders of the now-unlisted company hold a claim worth far more than the ₩60.8m market value at delisting.
-
Operating subsidiaries still generate revenue. LTM consolidated revenue to March 2026 was ₩11.9bn [S19]. Pharmatimes reported positive cumulative operating profit (about ₩0.4bn) through 3Q 2025 at the consolidated level [S6], so the operating subsidiaries are not necessarily loss-making on their own.
-
Legal recoveries. If the complaints over Gwangjin Sanjeon (₩6bn) and GN Equity (₩1.5bn) succeed, they could support civil recovery for the company [S12][S16].
Bear-case arguments
-
Equity is effectively stranded. Delisted shares lose market liquidity, and the final traded price of ₩2 [S28] reflects the market's view of recoverable value.
-
Book values are unreliable. The FY2025 disclaimer means asset carrying values, including the related-party acquisitions, have not been validated by an auditor [S2]. The complaint alleges the Gwangjin Sanjeon valuation was inflated by about ₩7.2bn above a 2022 reference [S16].
-
Creditors rank first. Total liabilities of ₩36.2bn exceed total assets less any impairment, with current liabilities about 2.5 times current assets [S20]. In any restructuring, CB holders and lenders, including holders of disputed CBs, rank ahead of equity.
Catalysts and monitorables (next 12 months)
| Item | Why it matters |
|---|---|
| Outcome of the injunction and any merits suit against KRX | Relisting after execution of delisting would be highly unusual; confirms finality |
| Prosecutorial decisions on the three criminal complaints | Possible indictments; potential civil recovery |
| Rulings on CB validity (41st and 42nd series) | Determines the liability structure |
| Any insolvency, rehabilitation or sale filing by BYON or CTM | Determines recovery for residual equity |
| Status of CM Tech and Gwangjin Sanjeon (sale or retention) | Main value-bearing assets |
| FY2026 audit (if any) | A going-concern assessment would indicate survivability |
Analyst verdict
BYON Co., Ltd. no longer has an investment case as a listed equity. It was delisted from KOSDAQ on 1 July 2026 after a final liquidation-trading window in which the shares fell to ₩2 [S1][S28]. The forensic lesson is more useful than any valuation.
Across four decades the company changed name five times and changed its business model at least four times. Each pivot coincided with a change of controlling shareholder rather than with a market opportunity it was equipped to capture. Its "bio" identity rested on a red-ginseng trading business that briefly benefited from COVID-era demand: FY2020 was the only year with a separate operating profit (₩2.68bn) [S18]. The identity also rested on a minority stake in someone else's stem-cell pipeline, while BYON's own R&D never exceeded about 3% of revenue [S19].
After CTM took control in late 2023, the company bought assets connected to its new owner. It funded them with convertible bonds that were later challenged in court, and it failed to disclose a control-transfer contract on time. Insiders filed three criminal complaints against management within two months [S12][S16][S17]. The exchange then removed the company on continuity and transparency grounds. A going-concern audit disclaimer [S2] and revenue below the KOSDAQ threshold [S4][S5] meant there were three independent paths to delisting by mid-2026.
For an analyst, BYON shows the pattern behind the KOSDAQ "zombie company" problem that drove the 2025–2026 reforms. Its warning signs were visible in the data years before the outcome: persistent losses, heavy reliance on CB financing, frequent control trades at large premiums to market, related-party asset purchases, and very small headcount. Residual value for former shareholders, if any, depends on asset realisation and legal recoveries outside the public market, and it ranks behind creditors.
Rating: Not rateable (delisted). Residual equity: speculative, with high risk of total loss.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure (as of Jun 2026) | Background | Age |
|---|---|---|---|---|
Ryu Jin-hyung (류진형) | CEO and Representative Director | Since 23 Jan 2024 (2.4 yrs) | CEO of Central Holdings; former CEO of Jungang Ocean Co., Ltd. [S21]. Asia Economy describes him as a former senior managing director of CTM [S16]. | 58 |
Jang Young-ho (장영호) | Representative Director | ~1.8 yrs | — | — |
Jeong Min-ho (정민호) | Inside Director | ~2.4 yrs | — | — |
Seo Dong-il (서동일) | Inside Director (listed by S&P); a Jan 2025 EGM agenda sought his removal | ~1.8 yrs | Filed three criminal complaints against management | — |
Jeong Haeng-ju (정행주) | Independent Outside Director | ~2.4 yrs | — | — |
Oh Byeong-hoon (오병훈) | Independent Outside Director | ~1.8 yrs | — | — |
Choi Yong-seok (최용석) | Statutory Auditor | ~2.4 yrs | Named as a respondent in the Dec 2024 complaint | — |
Lee Soo-yeon (이수연) | Statutory Auditor | ~1.8 yrs | Co-filed the Dec 2024 complaint against the CEO | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Period |
|---|---|---|
Lee Sung-min (이성민) | Former CEO; later associated with deals at Yujient and Jungang Ocean | To 2016 |
Kim Byung-joon (김병준) | CEO | 2016 – Jan 2024; also a selling shareholder in the 2023 CTM transaction |
Park Beom-jin (박범진), Park Jeong-han (박정한) | Listed as representatives on THE VC (date of service not confirmed) | Not confirmed |
Major Shareholders
| Date | Holder | Shares | Stake (%) |
|---|---|---|---|
Apr 2021 | W Global No.1 Union (largest shareholder; its own largest holder is Oncotrack and 2 others) | 6,603,188 | 9.87 |
Apr 2021 | Lee Jin-woong (related party) | 1,396,089 | 2.09 |
Apr 2021 | Total shares outstanding | 66,900,777 | 100.00 |
Nov 2023 | W Global No.1 Union + Kim Byung-joon (sold to CTM) | 3,560,436 | 9.37 |
Early 2024 | CTM after share purchase and ₩7.0bn allotment | — | 17.55 |
Jul 2024 | CTM (entire holding under transfer contract) | 3,560,436 | 7.95 |
“—” = not publicly disclosed.
Competitive Landscape
Competitors by Segment
| Segment | Representative competitors | BYON's relative position |
|---|---|---|
Red ginseng and health-food raw materials | Korea Ginseng Corp. (KT&G group); other ginseng processors and contract health-food manufacturers | Small trader-processor using partner farm supply and partner processing technology. Customer list included large buyers, but revenue peaked at ₩12.8bn in FY2020. |
Stem-cell therapies (via affiliate) | Pharmicell, Medipost, Anterogen, Corestem (Korean stem-cell developers) | Minority investor only; no approved product |
Stem-cell-ingredient cosmetics | Numerous Korean cosmeceutical brands and ODM makers | STEMELIN was a niche home-shopping brand; cosmetics revenue was ₩1.35bn in FY2020 |
Hydraulic machinery and heavy-equipment parts (CM Tech) | Korean hydraulic component makers serving the construction-equipment industry | Newly acquired subsidiary; no market share disclosed |
Ship components | Large pool of Gyeongsang-region shipbuilding suppliers | Trading presence; scale not disclosed |
Fuel sales | Refiners' distribution networks and independent distributors | Commodity trading; low margin |
Legacy PVC banners and flooring | Building-materials and film producers | Exited |
Peer Comparison FY2025
| Metric | BYON (FY2025, consolidated) | Peer comparison |
|---|---|---|
Revenue | ₩20.6bn [S19] | — |
Revenue growth | −23.6% | Not compiled |
Net margin | −32.1% | Not compiled |
R&D intensity | 0.10% | Not compiled |
Recent Developments
Earlier items from the build-up (Dec 2024 – Mar 2025) are included for context and marked.



